Fig. 3From: Continuous versus intermittent short-acting β2-agonists nebulization as first-line therapy in hospitalized children with severe asthma exacerbation: a propensity score matching analysisCompeting risk estimates for cumulative incidence of failure in nebulizationBack to article page